A Phase I Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT02922764

Study #:
STUDY00145969

Start Date:
Dec 27, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02922764

View Complete Trial Details & Eligibility at ClinicalTrials.gov